Publications by authors named "S P Becerra"
Article Synopsis
- The study investigated the use of transcranial focused ultrasound (tfUS) to treat patients with treatment-refractory generalized anxiety disorder (trGAD) by targeting the right amygdala.
- Twenty-five participants received eight weekly tfUS sessions and were assessed using anxiety measures such as the Hamilton Anxiety Inventory (HAM-A) and Beck Anxiety Inventory (BAI), showing significant reductions in anxiety levels post-treatment.
- The findings indicate that tfUS is a safe and potentially effective intervention for anxiety disorders, meriting further research into its applications for psychiatric and neurological conditions.
Background: Chile has made significant progress in recent decades in implementing policies to improve the efficiency of its health system with an impact on population health.
Aim: To present five case studies of successful policies whose impact has been documented.
Methods: Case study report.
Photoreceptor death causes blinding inheritable retinal diseases, such as retinitis pigmentosa (RP). As disease progression often outpaces therapeutic advances, finding effective treatments is urgent. This study focuses on developing a targeted approach by evaluating the efficacy of small peptides derived from pigment epithelium-derived factor (PEDF), known to restrict common cell death pathways associated with retinal diseases.
View Article and Find Full Text PDFBackground: The amygdala is highly implicated in an array of psychiatric disorders but is not accessible using currently available noninvasive neuromodulatory techniques. Low-intensity transcranial focused ultrasound (TFUS) is a neuromodulatory technique that has the capability of reaching subcortical regions noninvasively.
Methods: We studied healthy older adult participants ( = 21, ages 48-79 years) who received TFUS targeting the right amygdala and left entorhinal cortex (active control region) using a 2-visit within-participant crossover design.
Background: Alzheimer's disease (AD) is a progressive, multifactorial, neurodegenerative disorder affecting >6 million Americans. Chronic, low-grade neuroinflammation, and insulin resistance may drive AD pathogenesis. We explored the neurophysiological and neuropsychological effects of NE3107, an oral, anti-inflammatory, insulin-sensitizing molecule, in AD.
View Article and Find Full Text PDF